Achieves third quarter revenue growth of 9% reported and 8% organic, driven by CAG Diagnostics recurring revenue growth of 10% reported and 9% organic
Solid revenue growth reflects benefits from.
Records second quarter revenue growth of 10% reported and 10% organic, driven by CAG Diagnostics recurring revenue growth of 11% reported and 12% organic
Achieves record second quarter global.
02.05.2023 - IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. First Quarter Results The Company reports revenues of $900 million for the first quarter of 2023, an increase of 8% .
Achieves third quarter revenue growth of 4% reported and 8% organic, driven by CAG Diagnostics recurring revenue growth of 5% reported and 9% organic, building.